

## Ally Bridge Group finances 3 new Medtech investments with \$140 M

16 December 2019 | News

**Bringing Total Ally Bridge-led Private Life Science Investments to Above US\$500 million over the Last 18 Months**



Ally Bridge Group ("ABG"), a leading global life science investment group based in Hong Kong and New York, has announced that it recently led investments in three new medical technology companies. Each of the three companies is a commercial-stage, leading innovator re-setting the standard of care in its respective category. They include:

- **Imperative Care** (Campbell, CA) -- A company that is singularly dedicated to improving the way stroke is treated by advancing medical technology, equipping healthcare providers to evolve best practices and elevate the standard of care for stroke patients. Imperative Care has received FDA approval for its first families of access and aspiration catheters. Website: <http://www.imperativecare.com/>
- **Venclose Medical** (Santa Clara, CA) -- A commercial-stage company developing next-generation solutions for the treatment of venous reflux disease, also known as chronic venous insufficiency. Venclose has been commercializing in the US and Europe since 2018. Website: <http://www.venclose.com/>
- **Mavrik Dental Systems** (Tel Aviv, Israel) -- A company with proprietary technologies and products for in-office teeth whitening with unparalleled efficiency and outcomes, and gum care. Mavrik represents ABG's first investment in an Israel-based company. Website: <https://mavrikdental.com/>

"Medtech, as with biotech, remains a must-invest sector for ABG, where we focus on best-in-class technologies to disrupt current standards of care," said Frank Yu, CEO and CIO of Ally Bridge Group. "The closing of these investments brings the aggregate amount of ABG-led private life science investments to above \$500 mm over the last 18 months, which include ABG's lead role in investments in Grail (early cancer detection), Pulmonx (interventional pulmonology), Quantum Surgical (interventional oncology). All of these companies, with the exceptions of one in Israel and one in France, are based in Silicon Valley, California, USA."

"Our active investments that leverage powerful synergies across private and public markets, coupled with our M&A know-how and cross-border value-add, position ABG uniquely as a leading investor in late-stage best-in-class life science technologies", adds Yu.